Clover Biopharmaceuticals, Ltd.

HK$1.35As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2197Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 5Y CAGR (35.75%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 2.61
PE TTM 1.753
TSR TTM (38.64%)
Mkt cap HK$1.753B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.60
18.24%
(64.05%)
Hold 8|3|2|2|10
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.02
0.02
0.02
0.02
(3.32%)
0.90%
1.78%
11.18%
Revenue¥M
101.5
101.9
99.22
99.50
(5.51%)
(2.51%)
(7.29%)
(4.88%)
Peers (US$223.6M)
Cap (US$)
PE
249.9M
21.32x
Capital
TTM
5Y
10Y
Leveragex
1.026
0.134
0.123
EBIT/Intx
1.866
0.518
0.440
Own earn%
(35.62)
164.25
151.60
Sh yield%
33.08
43.42
44.16
Owners
Insiders/Inst%
10.98
44.97
Short interest%
3.65
SBC / revenue%
3.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
10–18
$1 testx
—
Incr. ROIC%
9